All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-06-06T12:34:21.000Z

EHA2022 abstracts: What's hot in AML?

By Claire Aukim-Hastie, Ella Dixon
Jun 6, 2022
Share:

Bookmark this article

To help navigate the exciting content being presented at the EHA2022 Congress, the AML Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in AML.

Patient selection for HSCT

P522

Absolute lymphocyte count is an independent survival predictor in patients with acute myeloid leukemia treated with intensive chemotherapy

S167

Prediction of relapse after allogeneic stem cell transplantation using individualized measurable residual disease markers; the prospective nordic study NMDSG14B

S238

Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT


Induction therapy

P103-2

Toward combinations: double and triple therapies

P581

Phase II study of lower-intensity frontline therapy for newly diagnosed patients with AML who are unfit or otherwise not eligible for frontline clinical trials

S125

10-day decitabine vs. conventional chemotherapy ('3+7') followed by allografting (HSCT) in AML patients ≥60 years: a randomized phase II study of the EORTC leukemia group, GIMEMA, CELG, and GMDS-SG

S126

Gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3 mutated AML. Results from the NCRI AML19 'MIDOTARG' pilot trial

S128

A randomised comparison of CPX-351 and FLAG-IDA in high risk acute myeloid leukaemia. Results from the NCRI AML19 trial


Biomarkers and prediction of response

P406

Enhanced significance of FLT3-ITD residual disease detection on treatment outcome in acute myeloid leukemia

P410

LPIN1 regulates lipid homeostasis and maintains stem cell enriched populations in AML

P430

Molecular characterization of clinical response in newly-diagnosed acute myeloid leukemia patients treated with ivosidenib + azacitidine compared to placebo + azacitidine

P470

NGS-based minimal residual disease detection in peripheral blood shows good prognostic value for OS and EFS in patients with acute myeloid leukemia recruited in the UNIFY trial

P498

Clinical and biological markers associated with long-term survival for patients with acute myeloid leukemia (AML) in remission after chemotherapy in the QUAZAR AML-001 trial of oral azacitidine

S130

NPM1 mutated AML: impact of co-mutational patterns - results of the European Harmony Alliance

S131

Clinical implications of secondary-AML type mutations in patients with de novo acute myeloid leukemia

S134

Intra-patient functional heterogeneity of AML determines first-line treatment response


Novel therapies

P510

The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia

P554

Gilteritinib versus salvage chemotherapy for relapsed/refractory FLT3-mutated acute myeloid leukemia: a phase 3, randomized, multicenter, open-label trial in Asia

P557

Hematologic improvements with ivosidenib + azacitidine compared with placebo + azacitidine in patients with newly-diagnosed acute myeloid leukemia

S100

Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed FLT3-ITD+ AML

S127

Quizartinib with decitabine and venetoclax (triplet) is active in patients with FLT3-ITD mutated acute myeloid leukemia - a phase I/II study

S132

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia: phase 1b results


Real-world data

P526

Real-world comparison of different treatment modalities for favorable risk acute myeloid leukemia: standard dose anthracycline vs high dose anthracycline vs addition of gemtuzumab ozogamicin

EHA2022 abstracts

To download this document, click below.

Download here

More about...
EHA 2022

Related articles

Add bookmark

What is the clinical significance of secondary-AML-type mutations in de novo AML?

During the EHA 2022 Congress, the AML Hub spoke with Isolda Fernandez, FUNDALEU, Buenos Aires, AR. We asked, What is the clinical significance of secondary-AML-type...

Aug 6, 2022
Add bookmark

What is the clinical significance of secondary-AML-type mutations in de novo AML?

During the EHA 2022 Congress, the AML Hub spoke with Isolda Fernandez, FUNDALEU, Buenos Aires, AR. We asked, What is...

Aug 6, 2022
Add bookmark

Visual abstract | QuANTUM-First trial of quizartinib with standard chemotherapy and as continuation therapy in newly diagnosed FLT3-ITD+ AML

The AML Hub is happy to present a Visual Abstract summarizing key data from the phase III QuANTUM-First...

Jul 19, 2022
Add bookmark

Visual abstract | QuANTUM-First trial of quizartinib with standard chemotherapy and as continuation therapy in newly diagnosed FLT3-ITD+ AML

The AML Hub is happy to present a Visual Abstract...

Jul 19, 2022

Newsletter

Subscribe to get the best content related to AML delivered to your inbox